26 February 2026
EMADOC-1700519818-2896158
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Jorveza

budesonide

On 26 February 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Jorveza. The marketing authorisation holder for this medicinal product is Dr. Falk Pharma GmbH.

The CHMP adopted a new pharmaceutical form, oral suspension, with a new strength, 0.2 mg/ml, associated with a new indication as follows:

> Jorveza 0.2 mg/mL oral suspension is indicated for the treatment of eosinophilic esophagitis (EoE) in paediatric patients 2 to 17 years of age.

The indication for Jorveza orodispersible tablets remains unchanged, as follows:

> Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age).

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union